Skip to main content
. 2019 Jul 24;6(17):1900782. doi: 10.1002/advs.201900782

Figure 1.

Figure 1

Vulnerabilities of TMZ identified by a genome‐wide pooled screening in EGFRvIII‐expressing GBM. a) Schematic representation of the flowchart of genome‐wide screening of EGFRvIII‐regulated/TMZ resistance‐associated genes using the pooled GeCKOv2 human lentiviral library. b) The sgRNAs of each gene were weighted, and 1287 and 1196 TMZ resistance‐associated genes were identified in U87EGFRvIII cells treated with TMZ at days 7 and 14, respectively (Table S5, Supporting Information). c) By comparing sgRNA profiles from the U87 and U87EGFRvIII cells following treatment with TMZ for 7 and 14 days, 981 and 929 differentially expressed genes were identified to be associated with TMZ resistance and sensitivity, respectively (Table S6, Supporting Information). d) Venn diagram shows differentially expressed genes in four groups described above: EGFRvIII‐expressing group (vIII), negative‐control group (NC), TMZ‐treated group (TMZ), and DMSO‐treated group (DMSO) (Table S7, Supporting Information).